Bellerophon Therapeutics, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Bellerophon Therapeutics, Inc. (NASDAQGM: BLPH) violated federal securities laws in connection with its initial public offering (“IPO”). Bellerophon, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.

Bellerophon’s Stock Suffers

On February 13, 2015, Bellerophon held its IPO, selling 13 million shares of stock and raising $60 million in new capital. However, since the IPO, Bellerophon’s stock has fallen drastically from its offering price of $12 per share to close at only $1.17 per share on October 31, 2016. The decline may be due to the fact that the company’s business operations and financial prospects were not as strong as represented in the company’s Registration Statement that it filed with the U.S. Securities and Exchange Commission.

Bellerophon Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: